Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Efficacy, Safety and Tolerability of Sexelaxin When Added to Standard Therapy in AHF (RELAX-AHF-ASIA)

12 de junho de 2019 atualizado por: Novartis Pharmaceuticals

A Multicenter, Randomized, Double-blind, Placebo Controlled Phase III Study to Evaluate the Efficacy, Safety and Tolerability of Serelaxin When Added to Standard Therapy in Acute Heart Failure Patients

The purpose of the study was to evaluate the efficacy, safety and tolerability of intravenous infusion of serelaxin, when added to standard therapy, in acute heart failure (AHF) patients.

Visão geral do estudo

Status

Rescindido

Condições

Intervenção / Tratamento

Tipo de estudo

Intervencional

Inscrição (Real)

876

Estágio

  • Fase 3

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Locais de estudo

  • China
      • Beijing, China, 100050
        • Novartis Investigative Site
      • Chongqing, China, 400037
        • Novartis Investigative Site
      • Shanghai City, China
        • Novartis Investigative Site
    • Beijing
      • Beijing, Beijing, China, 100039
        • Novartis Investigative Site
      • Beijing, Beijing, China, 100037
        • Novartis Investigative Site
    • Gansu
      • Lanzhou, Gansu, China, 730030
        • Novartis Investigative Site
    • Guangdong
      • Guangzhou, Guangdong, China, 51000
        • Novartis Investigative Site
      • Guangzhou, Guangdong, China, 510515
        • Novartis Investigative Site
    • Jiangsu
      • Suzhou, Jiangsu, China, 215006
        • Novartis Investigative Site
      • Yangzhou, Jiangsu, China
        • Novartis Investigative Site
    • Liaoning
      • Shenyang, Liaoning, China, 110000
        • Novartis Investigative Site
      • Shenyang, Liaoning, China, 110003
        • Novartis Investigative Site
    • Shanghai
      • Jinshan, Shanghai, China, 201508
        • Novartis Investigative Site
      • Shanghai, Shanghai, China, 200032
        • Novartis Investigative Site
    • Shanxi
      • Xian, Shanxi, China, 710061
        • Novartis Investigative Site
    • Tianjin
      • Tianjin, Tianjin, China, 300121
        • Novartis Investigative Site
    • Zhejiang
      • Hangzhou, Zhejiang, China, 310013
        • Novartis Investigative Site
      • Wenzhou, Zhejiang, China, 325000
        • Novartis Investigative Site
  • Cingapura
      • Singapore, Cingapura, 169609
        • Novartis Investigative Site
      • Singapore, Cingapura, 117549
        • Novartis Investigative Site
  • Filipinas
      • Makati City, Filipinas, 1229
        • Novartis Investigative Site
      • Manila, Filipinas, 1003
        • Novartis Investigative Site
      • Pasig City, Filipinas, 1605
        • Novartis Investigative Site
      • Quezon City, Filipinas, 1102
        • Novartis Investigative Site
      • Quezon City, Filipinas, 1113
        • Novartis Investigative Site
      • San Juan City, Filipinas, 1500
        • Novartis Investigative Site
    • Manila
      • Quezon City, Manila, Filipinas, 1100
        • Novartis Investigative Site
    • Metro Manila
      • Manila, Metro Manila, Filipinas, 1000
        • Novartis Investigative Site
  • Japão
      • Osaka, Japão, 534-0021
        • Novartis Investigative Site
      • Saitama, Japão, 330 8503
        • Novartis Investigative Site
    • Aichi
      • Nagakute-city, Aichi, Japão, 480-1195
        • Novartis Investigative Site
      • Seto-city, Aichi, Japão, 489-8642
        • Novartis Investigative Site
    • Chiba
      • Kamogawa-city, Chiba, Japão, 2968602
        • Novartis Investigative Site
    • Ehime
      • Saijo-city, Ehime, Japão, 793-0027
        • Novartis Investigative Site
    • Fukuka
      • Chikushino-city, Fukuka, Japão, 818-8516
        • Novartis Investigative Site
    • Fukuoka
      • Fukuoka-city, Fukuoka, Japão, 810-0001
        • Novartis Investigative Site
      • Fukuoka-city, Fukuoka, Japão, 811-0213
        • Novartis Investigative Site
      • Fukuoka-city, Fukuoka, Japão, 815-8588
        • Novartis Investigative Site
      • Iizuka-city, Fukuoka, Japão, 820-8505
        • Novartis Investigative Site
      • Kurume-city, Fukuoka, Japão, 830-8543
        • Novartis Investigative Site
      • Kurume-city, Fukuoka, Japão, 830-8577
        • Novartis Investigative Site
    • Gifu
      • Ogaki-city, Gifu, Japão, 503-8502
        • Novartis Investigative Site
    • Hokkaido
      • Kushiro-city, Hokkaido, Japão, 085-0062
        • Novartis Investigative Site
      • Sapporo-city, Hokkaido, Japão, 006-8555
        • Novartis Investigative Site
    • Hyogo
      • Amagasaki city, Hyogo, Japão, 660 8550
        • Novartis Investigative Site
      • Kobe-City, Hyogo, Japão, 654-0155
        • Novartis Investigative Site
    • Ibaraki
      • Mito-city, Ibaraki, Japão, 311-4198
        • Novartis Investigative Site
    • Ishikawa
      • Kanazawa, Ishikawa, Japão, 920 8650
        • Novartis Investigative Site
    • Kagawa
      • Kanonji-city, Kagawa, Japão, 769-1695
        • Novartis Investigative Site
      • Takamatsu city, Kagawa, Japão, 760 8557
        • Novartis Investigative Site
    • Kanagawa
      • Kawasaki-city, Kanagawa, Japão, 211-8533
        • Novartis Investigative Site
      • Yokohama city, Kanagawa, Japão, 232 0024
        • Novartis Investigative Site
      • Yokohama-city, Kanagawa, Japão, 236 0051
        • Novartis Investigative Site
      • Yokohama-city, Kanagawa, Japão, 227-8501
        • Novartis Investigative Site
      • Yokohama-city, Kanagawa, Japão, 231-8682
        • Novartis Investigative Site
    • Kochi
      • Kochi city, Kochi, Japão, 781 8555
        • Novartis Investigative Site
    • Kumamoto
      • Kumamoto-city, Kumamoto, Japão, 861-4193
        • Novartis Investigative Site
      • Yatsushiro-city, Kumamoto, Japão, 866-8660
        • Novartis Investigative Site
    • Kyoto
      • Kyoto-city, Kyoto, Japão, 607-8062
        • Novartis Investigative Site
      • Uji-city, Kyoto, Japão, 611-0042
        • Novartis Investigative Site
    • Miyagi
      • Sendai-city, Miyagi, Japão, 981-3133
        • Novartis Investigative Site
    • Nagano
      • Nakano-city, Nagano, Japão, 383-8505
        • Novartis Investigative Site
      • Saku-city, Nagano, Japão, 3850051
        • Novartis Investigative Site
      • Ueda-city, Nagano, Japão, 386-8610
        • Novartis Investigative Site
    • Niigata
      • Niigata-city, Niigata, Japão, 950-1197
        • Novartis Investigative Site
    • Osaka
      • Osaka-city, Osaka, Japão, 540-0006
        • Novartis Investigative Site
    • Saitama
      • Kawaguchi-city, Saitama, Japão, 333-0842
        • Novartis Investigative Site
      • Sayama-city, Saitama, Japão, 350-1323
        • Novartis Investigative Site
      • Wako-city, Saitama, Japão, 351-0102
        • Novartis Investigative Site
    • Shiga
      • Kusatsu city, Shiga, Japão, 525 8585
        • Novartis Investigative Site
    • Shizuoka
      • Hamamatsu-city, Shizuoka, Japão, 430-8558
        • Novartis Investigative Site
      • Kakegawa-city, Shizuoka, Japão, 436-8555
        • Novartis Investigative Site
    • Tokyo
      • Akishima-city, Tokyo, Japão, 196-0003
        • Novartis Investigative Site
      • Chuo ku, Tokyo, Japão, 104-8560
        • Novartis Investigative Site
      • Hachioji-city, Tokyo, Japão, 192-0918
        • Novartis Investigative Site
      • Itabashi-ku, Tokyo, Japão, 173-8610
        • Novartis Investigative Site
      • Musashino-city, Tokyo, Japão, 180-8610
        • Novartis Investigative Site
      • Shinagawa ku, Tokyo, Japão, 141 8625
        • Novartis Investigative Site
      • Shinagawa-ku, Tokyo, Japão, 142-8666
        • Novartis Investigative Site
    • Wakayama
      • Tanabe-city, Wakayama, Japão, 646-8558
        • Novartis Investigative Site
  • Jordânia
      • Amman, Jordânia, 11183
        • Novartis Investigative Site
      • Amman, Jordânia, 11184
        • Novartis Investigative Site
    • JOR
      • Amman, JOR, Jordânia, 11152
        • Novartis Investigative Site
  • Líbano
      • Ashrafieh, Líbano, 166830
        • Novartis Investigative Site
      • Beirut, Líbano, 1107 2020
        • Novartis Investigative Site
      • Beirut, Líbano
        • Novartis Investigative Site
      • Hazmieh, Líbano, 470
        • Novartis Investigative Site
  • Malásia
      • Kuala Lumpur, Malásia, 59100
        • Novartis Investigative Site
      • Kuala Lumpur, Malásia, 50400
        • Novartis Investigative Site
    • MYS
      • Kuala Lumpur, MYS, Malásia, 56000
        • Novartis Investigative Site
    • Sabah
      • Kota Kinabalu, Sabah, Malásia, 88300
        • Novartis Investigative Site
    • Sarawak
      • Kuching, Sarawak, Malásia, 94300
        • Novartis Investigative Site
    • Selangor Darul Ehsan
      • Kuala Lumpur, Selangor Darul Ehsan, Malásia, 43000
        • Novartis Investigative Site
      • Sungai Buloh, Selangor Darul Ehsan, Malásia, 47000
        • Novartis Investigative Site
  • Republica da Coréia
      • Busan, Republica da Coréia, 602739
        • Novartis Investigative Site
      • Gwangju, Republica da Coréia, 61469
        • Novartis Investigative Site
      • Incheon, Republica da Coréia, 405 760
        • Novartis Investigative Site
      • Seoul, Republica da Coréia, 03080
        • Novartis Investigative Site
      • Seoul, Republica da Coréia, 03722
        • Novartis Investigative Site
      • Seoul, Republica da Coréia, 02841
        • Novartis Investigative Site
    • Bucheon Si
      • Gyeonggi do, Bucheon Si, Republica da Coréia, 422-711
        • Novartis Investigative Site
    • Chungcheongbuk Do
      • Cheongju si, Chungcheongbuk Do, Republica da Coréia, 28644
        • Novartis Investigative Site
    • Gangwon-do
      • Wonju, Gangwon-do, Republica da Coréia, 26427
        • Novartis Investigative Site
    • Gyeonggi Do
      • Bundang Gu, Gyeonggi Do, Republica da Coréia, 13620
        • Novartis Investigative Site
    • Korea
      • Seoul, Korea, Republica da Coréia, 05505
        • Novartis Investigative Site
      • Seoul, Korea, Republica da Coréia, 06351
        • Novartis Investigative Site
      • Seoul, Korea, Republica da Coréia, 08308
        • Novartis Investigative Site
    • Seocho Gu
      • Seoul, Seocho Gu, Republica da Coréia, 06591
        • Novartis Investigative Site
  • Tailândia
      • Bangkok, Tailândia, 10330
        • Novartis Investigative Site
      • Bangkok, Tailândia, 10700
        • Novartis Investigative Site
      • Bangkok, Tailândia, 10400
        • Novartis Investigative Site
      • Chiang Mai, Tailândia, 50200
        • Novartis Investigative Site
      • Muang, Tailândia, 40002
        • Novartis Investigative Site
    • Hat Yai
      • Songkhla, Hat Yai, Tailândia, 90110
        • Novartis Investigative Site
  • Taiwan
      • Changhua, Taiwan, 50006
        • Novartis Investigative Site
      • Kaohsiung, Taiwan, 80756
        • Novartis Investigative Site
      • Kaohsiung City, Taiwan, 83301
        • Novartis Investigative Site
      • New Taipei, Taiwan, 22060
        • Novartis Investigative Site
      • Taichung, Taiwan, 40447
        • Novartis Investigative Site
      • Taipei, Taiwan, 10002
        • Novartis Investigative Site
      • Taipei, Taiwan, 11217
        • Novartis Investigative Site
      • Taipei, Taiwan, 10449
        • Novartis Investigative Site
      • Taoyuan, Taiwan, 33305
        • Novartis Investigative Site
      • Yilan, Taiwan, 26058
        • Novartis Investigative Site
  • Índia
      • Rajasthan, Índia, 334003
        • Novartis Investigative Site
    • Delhi
      • New Delhi, Delhi, Índia, 110029
        • Novartis Investigative Site
    • Gujarat
      • Ahmedabad, Gujarat, Índia, 380054
        • Novartis Investigative Site
      • Vadodara, Gujarat, Índia, 390022
        • Novartis Investigative Site
    • Maharashtra
      • Nagpur, Maharashtra, Índia, 440010
        • Novartis Investigative Site
      • Nagpur, Maharashtra, Índia, 440012
        • Novartis Investigative Site
    • Tamil Nadu
      • Chennai, Tamil Nadu, Índia, 600101
        • Novartis Investigative Site
    • Telangana
      • Hyderabad, Telangana, Índia, 500082
        • Novartis Investigative Site

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

18 anos e mais velhos (Adulto, Adulto mais velho)

Aceita Voluntários Saudáveis

Não

Gêneros Elegíveis para o Estudo

Tudo

Descrição

Inclusion Criteria:

  • Male or female ≥ 18 years of age, with body weight ≤160 kg

  • Hospitalized for AHF; AHF is defined as including all of the following measured at any time between presentation (including the emergency department and outpatient clinic) and at the end of screening:

    • Persistent dyspnea at rest or with minimal exertion at screening and at the time of randomization
    • Pulmonary congestion on chest radiograph
    • Brain natriuretic peptide (BNP) ≥500 pg/mL or NT-proBNP ≥2,000 pg/mL
  • Systolic BP ≥125 mmHg at the start and at the end of screening
  • Able to be randomized within 16 hours from presentation to the hospital, including the emergency department and outpatient clinic
  • Received intravenous furosemide of at least 40 mg total (or equivalent) at any time between presentation (this includes outpatient clinic, ambulance, or hospital including emergency department) and the start of screening for the study for the treatment of the current acute HF episode
  • Renal impairment defined as an estimate glomerular filtration rate using the between presentation and randomization of ≥ 25 and ≤75mL/min/1.73m2, calculated using the Modification of Diet in Renal Disease formula (or modified sMDRD formula according to specific ethnic groups and local practice guidelines).

Exclusion Criteria:

  • Dyspnea primarily due to non-cardiac causes
  • Temperature >38.5°C (oral or equivalent), sepsis, active and clinically significant infection requiring IV anti-microbial treatment or known presence or evidence of Human Immunodeficiency Virus (HIV) infection (based on history and/or clinical findings, including laboratory results obtained during screening period).

  • Clinical evidence of acute coronary syndrome currently or within 30 days prior to enrollment

    *Patients with systolic blood pressure >180 mmHg at the end of screening

  • AHF due to significant arrhythmias, which include any of the following: sustained ventricular tachycardia, bradycardia with sustained ventricular rate <45 beats per minute, or atrial fibrillation/flutter with sustained ventricular response of >130 beats per minute

  • Hepatic disease unrelated to Heart Failure etiology and as determined by any one of the following: AST and/or ALT values exceeding 3 X ULN and/or bilirubin > 1.5 X ULN at screening or history of hepatic encephalopathy, esophageal varices, or portacaval shunt, or a diagnosis of cirrhosis by any means, or evidence of chronic Hepatitis B (presence of hepatitis B surface antigen production: positive HBsAg), or chronic Hepatitis C infection (presence of Hepatitis C genetic replication: positive Hepatitis C viral RNA, based on history and/or clinical findings, including laboratory results obtained during screening period).

    *Significant uncorrected left ventricular outflow obstruction, such as obstructive hypertrophic cardiomyopathy or severe aortic stenosis (i.e., aortic valve area <1.0 cm2 or mean gradient >50 mmHg on prior or current echocardiogram), and severe mitral stenosis

  • History of malignancy of any organ system (other than localized basal cell carcinoma of the skin), treated or untreated, within the past year with a life expectancy less than 1 year

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Tratamento
  • Alocação: Randomizado
  • Modelo Intervencional: Atribuição Paralela
  • Mascaramento: Quadruplicar

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Comparador de Placebo: Placebo
Patients will receive continuous intravenous infusion of matching placebo serelaxin for 48 hours.
Medicamento: Placebo
Infusão intravenosa
Outro: Standard of CareTherapy
This treatment can include but is not limited to intravenous and/or oral diuretics, ACE inhibitors/angiotensin receptor antagonists, β blockers, and aldosterone receptor antagonists, etc.
Experimental: Serelaxin
Patients will receive continuous intravenous infusion of serelaxin(30 µg/kg/day) for 48 hours.
Outro: Standard of CareTherapy
This treatment can include but is not limited to intravenous and/or oral diuretics, ACE inhibitors/angiotensin receptor antagonists, β blockers, and aldosterone receptor antagonists, etc.
Medicamento: Serelaxina
Infusão intravenosa

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Percentage of Patients With a Clinical Composite Endpoint of Treatment Success, Treatment Failure, or no Change.
Prazo: through day 5
The trichotomous clinical composite endpoint of treatment success, treatment failure, or no change. Treatment success defined as improvement of dyspnea by Likert scale and at least 2 points improvement by at least 2 physician assessed signs and symptoms (orthopnea, rales edema, and jugular venous pulse) at Day 2; treatment failure defined as worsening heart failure, death, or re-hospitalization due to heart failure or renal failure through Day 5; no change defined as neither the criteria for treatment success nor the criteria for treatment failure was met through Day 5.
through day 5

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
Time to WHF
Prazo: Through Day 5
Results are given in terms of number of participants with at least one worsening heart failure (WHF) event through day 5 (pre-defined timeframe).
Through Day 5
Time to CV Death
Prazo: Through Day 180
analysis of time to CEC CV death through day 180 : results are given in terms of number of participants with CV death event through day 180 (pre-defined timeframe).
Through Day 180
Time to All-cause Death
Prazo: Through Day 180
Results are given in terms of number of participants with all cause death event through day 180 (pre-defined timeframe).
Through Day 180
Time to Moderate or Marked Improvements in Dyspnea by Likert Scale, Expressed in Days
Prazo: Through Day 5
Time to event is computed as the number of days from randomization to moderate or marked improvements in dyspnea by Likert scale
Through Day 5
Dyspnea by VAS-AUC Changes
Prazo: Through Day 5
Change from baseline in Dyspena by VAS-AUC through Day 5, expressed in mm-hours
Through Day 5
Length of Intensive Care Unit (ICU) and/or Coronary Care Unit (CCU) Stay for the Index AHF Hospitalization
Prazo: Up to day 30
Length of stay will be defined as the hospitalization discharge date and the time minus the baseline date and time plus 1 day
Up to day 30
Renal Dysfunction and Prevention of Worsening of Renal Function
Prazo: Through Day 5
number of participants with renal dysfunction or in-hospital worsening of renal function through Day 5
Through Day 5
Time to Re-hospitalization Due to Heart Failure and Renal Impairment
Prazo: Through Day 180
Time to event is computed as the number of days from randomization to re-hospitalization due to Heart Failure and renal impairment
Through Day 180
Time to CV Death or Re-hospitalization Due to Heart Failure/ Renal Failure
Prazo: Through Day 180
Results are given in terms of number of participants with CV death or at least one re-hospitalization due to Heart Failure through day 180 (pre-defined timeframe).
Through Day 180
Time to In-hospital Worsening Heart Failure Through Day 5
Prazo: Through Day 5
Results are given in terms of number of participants with at least one in-hospital worsening heart failure through day 5 (pre-defined timeframe). In-hospital worsening heart failure is defined by symptoms only, signs only, and both symptoms and signs.
Through Day 5
Use of Loop Diuretic and Vasoactive Agents
Prazo: Through Day 5
Number of patients reported with use of loop diuretic and vasoactive agents from randomization through Day 5
Through Day 5
Change From Baseline in Cardio-renal Biomarkers
Prazo: Day 2 and Day 5
Day 2 and Day 5
Number of Patients Reported With Total Adverse Events, Serious Adverse Events and Death.
Prazo: For the safety evaluation, all adverse events will be collected from signing of the informed consent form through Day 5 for non-serious AEs and through Day 14 for serious AEs.
To evaluate the safety and tolerability of intravenous serelaxin in AHF patients, number of patients with total adverse events, serious adverse events and death will be analyzed.
For the safety evaluation, all adverse events will be collected from signing of the informed consent form through Day 5 for non-serious AEs and through Day 14 for serious AEs.

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Patrocinador

Novartis Pharmaceuticals

Publicações e links úteis

A pessoa responsável por inserir informações sobre o estudo fornece voluntariamente essas publicações. Estes podem ser sobre qualquer coisa relacionada ao estudo.

Publicações Gerais

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Real)

12 de março de 2014

Conclusão Primária (Real)

27 de março de 2017

Conclusão do estudo (Real)

16 de junho de 2017

Datas de inscrição no estudo

Enviado pela primeira vez

20 de novembro de 2013

Enviado pela primeira vez que atendeu aos critérios de CQ

9 de dezembro de 2013

Primeira postagem (Estimativa)

11 de dezembro de 2013

Atualizações de registro de estudo

Última Atualização Postada (Real)

2 de agosto de 2019

Última atualização enviada que atendeu aos critérios de controle de qualidade

12 de junho de 2019

Última verificação

1 de junho de 2019

Mais Informações

Termos relacionados a este estudo

Palavras-chave

Termos MeSH relevantes adicionais

Outros números de identificação do estudo

  • CRLX030A2302

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .

Ensaios clínicos em Insuficiência Cardíaca Aguda

Ensaios clínicos em Placebo

Pesquisar ensaios semelhantes

Patrocinadores e Colaboradores

Condições médicas

Intervenções de drogas

CROs by country

CROs in Jamaica

Condições

Doenças Raras

Intervenções de drogas

Suplementos Alimentares

Patrocinador / Colaboradores

Localizações

Se inscrever